ARCHIVES

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

This article is from The Cancer Letter archive.

Vol. 40 No. 25 | June 20, 2014

Download PDF Visit The Full Archive

Related Articles

Phase III Study: Lymphoseek Superior to Vital Blue Dye

June 24, 2011

O’Connor Is New NS President, Curtiss Is Next

May 24, 1991

Research Integrity: Collins’ Student Falsified Data, ORI Finds

August 22, 1997

Gavel Changes Hands At NCAB, Korn advises New Members On Role

February 8, 1991

Cancer & The Media: Klausner, Watson Dispute Comments In New York Times Story

May 8, 1998

ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications

July 22, 2011